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Abstract 
Identifying emotions correctly is essential for successful social interaction. There is therefore 
a keen interest in designing therapeutic interventions to improve emotion recognition in 
individuals who struggle with social interaction. The neuropeptide oxytocin has been 
proposed as a potential physiological intervention due to its important role in emotion 
recognition and other aspects of social cognition. However, there are a number of caveats to 
consider with the current form of intranasal oxytocin commonly used in the literature. 
Psychological interventions, on the other hand, do not carry the same caveats, and there is 
therefore a need to understand how intranasal oxytocin administration compares to 
psychological interventions designed to target the same psychological phenomena; and 
whether a combined intervention approach may provide additive benefits. Here we present a 
pilot, proof of concept study in healthy volunteers comparing the effect of intranasal oxytocin 
against a validated emotion training program, finding that the psychological intervention, and 
not intranasal oxytocin, improved emotion recognition specifically for angry expressions. We 
discuss the theoretical implications of the research for future clinical trials. 
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The ability to recognise and successfully interpret another person’s emotions, emotion 
recognition, is essential in developing and maintaining social relationships, and poor emotion 
recognition is a risk factor for various psychiatric disorders [1]. Good emotion recognition 
therefore not only reduces the risk of developing poor mental health, but also enables an 
individual to pursue a successful social life. The neuropeptide oxytocin (OT) has been found 
to play an important role in social cognition, and specifically, in improving emotion 
recognition [2–5]. This research has encouraged significant interest in the therapeutic 
potential of intranasal OT (IN-OT) as an intervention for individuals with emotion 
recognition difficulties [6]. Numerous randomised control trials have investigated the benefit 
of OT administration in various clinical populations, including autism spectrum disorder [7–
19], schizophrenia [20–31], post-traumatic stress disorder [32,33], Prader-Willi syndrome 
[34], social anxiety disorder [35] and postnatal depression [36]. The success of these trials, 
however, has been mixed. One potential explanation for this, is that IN-OT has several 
caveats that limit its current usefulness. 
 Firstly, the pharmacokinetics of IN-OT administration are not fully understood. 
Consequently, it is not clear how many doses per day it would be necessary to prescribe to 
achieve the elevated OT concentrations that are associated with positive effects on social 
cognition. Based on current research [37–40], this may require several doses per day, which 
carries both cost and convenience considerations. Secondly, intranasal administration of OT 
is not straight forward. Indeed, researchers follow complicated guidelines [41] which would 
need to be imparted to patients to ensure correct administration. Thirdly, despite the 
enthusiasm to utilise IN-OT as a therapeutic intervention, relatively little research has 
investigated the long-term effects of administration, either pharmacokinetically or 
behaviourally [8,42,43]. Thus, there are a number of caveats to bear in mind when 
considering IN-OT as a therapeutic intervention. 
Conversely, psychological interventions are typically cheaper and easier to 
disseminate. Several psychological interventions have been created to improve social 
interaction in autism [44,45] and schizophrenia [46,47]. Emotion recognition training, 
however, not only offers a discrete targeted intervention and measurable outcome, but also 
the potential for wider positive effects on social behaviour. A detailed discussion regarding 
the potential of emotion training as an intervention is provided by Hunnikin and Van Goozen 
[48]. One such intervention, the Cardiff Emotion Recognition Training (CERT) program, has 
been found to not only increase emotion recognition, but also improve longer term, 
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objectively recorded social behaviour [49,50]. In contrast, the long-term effects of IN-OT 
administration are not fully understood. There is therefore a need to understand whether a 
psychological intervention, like CERT, is as effective at improving emotion recognition, 
compared to IN-OT. 
 There is, however, theoretical rationale to suggest that a combined intervention 
strategy incorporating IN-OT with a psychological intervention designed to improve social 
functioning, could provide additive benefits. The social salience hypothesis [51,52] of OT 
proposes that OT increases one’s awareness of social cues in the environment. Therefore, 
presenting social cues under the influence of IN-OT may increase the salience of these cues, 
and therefore bolster the success of the intervention. Indeed, a handful of studies have 
investigated this theoretical understanding1. The first such study administered IN-OT/placebo 
(twice daily) for 6 weeks to young adults with early psychosis with an additional dosage 
before each psychological intervention session (two hours each week, for 6 weeks), finding 
no additive effect of OT to the training [53]. Another study also investigated the additive 
effect of IN-OT (versus placebo) to social skills training in adults with schizophrenia, finding 
no evidence for this effect or an effect of training [54,55]. These studies, however, added a 
physiological intervention to a psychological intervention, and it was therefore not possible to 
ascertain whether IN-OT alone or training alone afforded the most social benefit. To our 
knowledge, only two studies to date have implemented this full (2x2) design, investigating 
whether a single administration of cognitive bias training and/or IN-OT in young children 
[56] and healthy students [57] improved feelings of maternal support or social imagery, 
respectively. Both studies, however, report null effects for IN-OT, but crucially also for all or 
some aspects of their psychological intervention, and it is therefore difficult to compare 
whether IN-OT or training had any/the most social benefit. 
All four studies reported no additional benefit of IN-OT. One potential explanation 
for this is that the psychological interventions used were aimed at either large social 
constructs (i.e., social functioning) or social biases. Although the OT literature has suggested 
OT plays a diverse role in social behaviour, the most robust finding is that IN-OT increases 
emotion recognition [2–5]. A psychological intervention targeting emotion recognition 
specifically would therefore not only help focus the content of the psychological intervention, 
but also focus on one of the most reliable IN-OT findings. 
 
1 Of note, only Cacciotti-Saija et al. (2014) had been published when the current study was designed. The four 
remaining papers were published after data collection for the current study had finished. 
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There are, however, several known moderators of the effect of IN-OT. First, OT 
effects are often emotion-specific. For example, a recent meta-analysis found that although 
there was an overall effect of OT on emotion recognition, this was driven by effects of OT on 
happy and fearful faces specifically [2]. Second, OT effects tend to be stronger for those with 
social difficulties [51]; indeed this is a stronger driver for the therapeutic interest in OT. 
Relatedly, OT effects have also been shown to be moderated by task difficulty (for example 
by manipulating emotional intensity or stimulus duration) [2,51]. Thus, it will also be 
important for research to understand whether there are emotion-specific differences between 
IN-OT and CERT, and for whom these interventions may provide the biggest benefit. 
Here we present a pilot, proof of concept study in which we compared IN-OT against 
a psychological intervention designed to improve emotion recognition, the CERT, in healthy 
volunteers. Firstly, we sought to compare the effect of the CERT against IN-OT (compared 
to their respective control conditions). Secondly, incorporating the social salience hypothesis, 
we hypothesised that the emotional cues presented during the CERT would become more 
salient to an individual who receive IN-OT before completing the training. It follows that if 
the cues presented during the training are more salient, one would anticipate that IN-OT 
would have a synergistic effect on the outcomes of the training, resulting in improved 
emotion recognition. In summary, we examined the effect of each intervention on emotion 
recognition: in isolation; in combination; and compared to their respective control conditions.  
 
Methods 
Participants and Ethics 
One hundred and four male undergraduates (Mage = 19.90, SE = 2.26) from Cardiff 
University took part in the study. The study aimed to recruit 120 participants. This value was 
determined based on previous OT administration studies in healthy populations [2,58]. As 
such, the study aimed to recruit more than double the standard sample size of previous 
studies, while acknowledging that the purpose of the study was to serve as pilot data for 
future research. Ultimately, 104 participants took part in the study, and no participants were 
lost across the two testing sessions. Data collection occurred between January - November 
2018. The study was approved by the School of Psychology Ethics Committee at Cardiff 
University (EC.17.03.14.4860R) and adhered to the Declaration of Helsinki. Participants 
from the School of Psychology were recruited via an online participation system; participants 
from other schools were recruited via an email advert. Participants were required to pass 
medical screening before taking part in the study, provided written informed consent prior to 
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taking part and a signed statement of health before leaving the testing facility. Participants 
were not allowed to take part if they had a history of cardiovascular disease, neurological or 
mental health disorders. They were asked to avoid alcohol consumption 24 hours prior to 
their session, and to avoid smoking and caffeine 2 hours before. Female participants were 
excluded from taking part because i) they would be required to take a pregnancy test prior to 
taking part, presenting additional ethical concerns; and ii) there is some evidence that OT 
concentrations fluctuate during the menstrual cycle [59,60] and that this is affected by 
contraceptives [59]. Participants from the School of Psychology were awarded course credits 
in compensation for taking part; participants from other schools were paid for taking part.  
 
Cardiff Emotion Recognition Training (CERT) 
In the present study, participants completed a shortened version of the CERT training [49,50] 
(https://emotionrecognition.cardiff.ac.uk/index.php) focusing on learning to recognise four 
basic emotions (happy, sad, fear, and anger). In the current version of the training, 
participants begin with a specific introduction to the four different emotions, describing their 
similarities and differences using well-validated pre-existing stimuli [61]. Participants then 
completed different activities including being presented with four emotions and asked to click 
on the correct facial expression for the emotion label shown (see Figure 1a), being asked to 
compare facial expression for similar features, and matching emotional expressions to 
emotional vignettes (see Figure 1b). 
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Figure 1 – Illustrative examples of trials from the CERT including when participants had to 
select the correct facial expression a) based on the emotion label shown and b) on the 





A control training program was designed to control for exposure to faces and attending to 
various facial features. In this way, any differences between the CERT and control training 
condition could be associated specifically with attaining to emotional cues, as opposed to 
faces in general or the eye and mouth regions of the face. Participants were asked to identify 
eye colour, hair colour, and gender of faces presented. Participants were therefore asked to 
look globally at the face to ascertain gender, but also locally to focus on specific regions of 
the face, such as the eyes and hair. Faces were presented in three blocks, in an attempt to 
replicate the different activities and increasing difficulty presented in the CERT; in the first 
block the faces were presented upright, in the second block the faces were Thatcherized [62], 
in the final block the faces were presented upside down [62]. The order of questions 
regarding eye/hair colour and gender were randomised across blocks.  
 
Facial Expression Recognition (FER) Task 
A modified version of the FER task from Hubble et al. (2017) was used to assess 
participants’ accuracy in identifying facial expressions of emotion. Participants saw three 
male and three female actors from the Ekman and Friesen (1975) series, representing the 
same four basic emotions that participants were trained on during the CERT (happy, sad, fear, 
and anger) and a neutral expression. Emotional expressions were presented at two different 
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intensities (high and low; differing intensities were created by morphing each expression with 
the actors’ neutral face), for three different durations (200ms, 300ms, and 600ms).  
We recruited healthy males who we were expected to present with average emotion 
recognition ability, and as such would recognise easy items (those that were high intensity 
and presented for longer) at 80-90% accuracy. Therefore, careful consideration was given to 
create a range of difficulty during the task, in anticipation that effects from the interventions 
might be tested more accurately for harder items. Moreover, research suggests that 300ms 
provides an interesting cut-off between implicit and explicit effects on IN-OT [2].  
Participants saw a total of 162 faces: six times for each unique variable combination 
for emotional expressions, and once for each neutral face at all three durations (because 
intensity is not applicable to neutral faces). A trial consisted of a black screen for 500ms, then 
a black screen with a white fixation cross for another 500ms, then a face was presented (for 
either 200, 300, or 600ms), immediately after the face disappeared, participants were asked to 
identify the emotion using a forced-choice paradigm. When participants had selected their 
answer, the next trial began, consequently there was no missing data for this task. The task 
was presented using Tobii Studio (https://www.tobii.com/).  
Participants completed the FER twice (first at least 2 weeks before their experimental 
session to assess baseline emotion recognition accuracy). Two fixed, queso-random versions 
of the task were created in order to 1) ensure the participants saw the same faces but in a 
different order each time to avoid learning effects, and 2) to ensure that participants did not, 
by chance, see a long sequence of one particular emotion. For each session, an average 
percentage recognition accuracy score was created for each emotion, intensity and duration. 
Finally, to examine the effect of the interventions, participants baseline scores were 
subtracted from their experimental session scores. In this way, positive values indicate that 
participants identified more facial expressions correctly after the experimental session, 
negative values indicate that they identified fewer facial expressions, and 0 indicates that 
their emotion recognition was exactly the same. 
 
Protocol 
Participants took part in a randomised, double-blind, placebo-controlled, between-subjects 
study. On arrival, participants provided written informed consent and completed the Emotion 
Quotient [EQ; 64], Autism Quotient-Short AQ [AQ-S; 65], and the State and Trait Anxiety 
Index [STAI; 66], before self-administering either a placebo (PL) nasal spray which was 
chemically matched to the OT spray apart from the active ingredient or 24IU (three puffs of 4 
 8 
IU per nostril) of OT. Sprays were administered in line with detailed guidelines [41] and 
under the supervision of the experimenter (KD; to eliminate inter-experimenter effects, KD 
conducted all experimental testing). Both nasal sprays were manufactured by St Mary’s 
Pharmaceutical Unit, Cardiff (http://www.wales.nhs.uk/sites3/home.cfm?orgid=828), in line 
with a randomisation list created by an independent researcher. Nasal spray administration 
was double-blind, bottles were numbered and given in sequential order. Participants were 
blind to training condition, but the experimenter was aware in order to load the correct 
training program. Training condition was assigned on an alternating basis. Participants then 
completed the 2-scale version of the Wechsler Abbreviated Scale of Intelligence [67] as a 
filler task for 30 minutes to ensure training was completed under peak OT concentrations 
[37–39]. At this time, participants completed either the CERT or the control training 
program, which took approximately 15 minutes to complete. Immediately after the training, 
participants completed the FER (also taking approximately 15 minutes to complete). 
Participants completed a further 30 minutes’ worth of social cognition tasks before being 
fully debriefed at the end of the study.  
 
Data Analysis 
A 2 (Drug: OT/PL) x 2 (Training: CERT/control) x 4 (Emotion: happy/sad/anger/fear) x 3 
(Duration: 200/300/600) x 2 (Intensity: high/low) mixed-model Analysis of Variance 
(ANOVA) was carried out, with the first two factors being between-subjects, and the 
remaining factors being within-subjects.  Normality was assessed using skewness values and 
was within acceptable levels. For all analyses, where the assumption of sphericity was not 
met, Greenhouse-Geisser values are reported. Interaction effects were decomposed using 
simple effects analysis and all comparisons were Bonferroni corrected. The main effects and 
interactions regarding emotion, intensity, and duration were in line with hypotheses and are 
not the primary focus of this paper; these are reported in the Supplemental Material (S1). The 
data were analysed using SPSS 25 [68]. All data and analysis code for the present study are 
available on OSF (https://osf.io/cbfru/). 
Finally, the questionnaire data for the EQ, AQ-S and STAI were averaged across their 
respective subscales and reliability analyses performed on the relevant subscales. For the 
purposes of this study, only the trait subscale of the STAI, social skills and mind reading of 
the AQ-S and overall EQ were chosen because we were only interested in trait assessments 
and did not anticipate a high prevalence of autistic traits assessed by the remaining subscales 
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of the AQ-S. All subscales achieved good reliability scores (Cronbach’s  ≥ .667), apart 
from the EQ (Cronbach’s  = .505) which was not analysed further. 
 
Results 
First, to confirm that there were no differences in baseline emotion recognition across 
experimental groups, a separate univariate ANOVA was carried out. As expected, there was 
no significant difference in baseline FER performance across the four groups (F(3, 100) = 
.255, p = .857, 
 = .008). Secondly, to confirm that there were no differences in social traits 
across experimental groups, a one-way ANOVA was carried out. As expected, there was no 
significant difference across the four groups for trait anxiety, F(3, 100) = .359, p = .782, 
mind reading, F(3, 100) = .615, p = .607, or social skills, F(3, 100) = 1.083, p = .360. Table 
1 provides a summary of sample characteristics across the experimental groups. 
 
Table 1 – Sample size and descriptives (mean and standard deviation) for participants’ self-














Placebo, Control 26 44.0(11.0) 2.9(0.5) 2.9(0.3) 82.8(7.9) 
Placebo, Training 28 44.9(9.2) 3.0(0.6) 2.8(0.4) 82.7(7.3) 
Oxytocin, Control 24 42.3(8.8) 3.0(0.6) 3.0(0.6) 82.8(5.5) 
Oxytocin, Training 26 42.8(11.1) 3.1(0.5) 3.0(0.5) 81.4(7.1) 
 
 
The main model revealed that there was no main effect of training, F(1, 100) = 2.921, p = 
.091, 
 = .028, or drug, F(1, 100) = .094, p = .759, 
 = .001 (see Figure 2) and no 
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interaction, F(1, 100) = .466, p = .497, 
 = .005 (see Figure 3). However, there were several 
significant interactions with training. 
There was a significant interaction between duration and training, F(1.87, 187.20) = 
4.308, p = .017, 
 = .041, such that, when collapsing across all emotions, participants who 
completed CERT identified more facial expressions correctly at 300ms, compared to those 
who completed the control training (there were no differences for 200ms or 600ms). This 
lower order interaction was moderated by emotion in 3-way interaction between emotion, 
duration, and training, F(5.35, 534.58) = 2.182, p = .051, 
 = .024. Participants who 
completed CERT specifically identified more angry facial expressions correctly, compared to 
those who completed the control training, when faces were presented for 200ms and 300ms 
(but not at 600ms); and identified more sad facial expressions correctly, compared to those 
who completed the control training, when faces were presented for 300ms (but not at 200ms 
or 600ms). There were no significant effects for happy or fearful expressions.  
This interaction was further qualified by intensity, F(4.88, 488.02) = 2.161, p = .059, 

 = .021, revealing that the previous findings were split by the emotional intensity of the 
facial expressions. Participants who completed CERT identified more low intensity angry 
expressions correctly but only when they were presented for 200ms (and not at 300ms or 
600ms) but identified more high intensity angry expressions correctly when presented for 
300ms (and not at 200ms). Interestingly, they identified significantly fewer high intensity 
angry expressions correctly when presented at 600ms. Moreover, the previous finding 
regarding sad facial expressions was also moderated by emotional intensity, such that 
participants who completed CERT specifically identified more high intensity sad expressions 
presented at 300ms (and not at 200ms or 600ms, or any duration at low intensity). Finally, 
there were also significant effects on happy and fearful expressions, such that participants 
who completed CERT identified more low intensity happy expressions presented for 300ms 
(and not 200ms or 600ms), and more low intensity fearful expressions presented for 600ms 
(and not 200ms or 300ms).  
Finally, there was a trend towards a significant 4-way interaction between emotion, 
intensity, training and drug condition, F(3, 300) = 2.392, p = .069, 
 = .023. Participants in 
the placebo condition who completed CERT identified more low intensity angry facial 
expressions correctly, compared to those who completed the control training (F(1, 100) = 
7.655, p = .007, 
 = .071). There was no corresponding improvement for those in the 
oxytocin condition (F(1, 100) = .034, p = .854, 
 < .001). Those in the oxytocin condition 
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who completed CERT did, however, identify more low intensity happy expressions correctly, 
compared to those who completed the control training (F(1, 100) = 3.895, p = .051, 
 = 
.037). Again, there was no corresponding improvement for those in the placebo condition 
(F(1, 100) = .059, p = .808, 
 = .001). It should be noted, however, that when simple effects 
analyses were carried out to examine direct differences between drug conditions, no 
significant results were found. Thus, strong caution is advised when reflecting on these 
findings.   
 








There are two key findings from this analysis: that there was a consistent effect of 
CERT on recognising angry expressions; and, as might be expected, the healthy males 
recruited to the pilot study had good emotion recognition ability. In order to understand what 
the possible effects of intervention might be for individuals with emotion recognition 
difficulty, we carried out an exploratory follow-up analysis based on these results: first, in 
order to avoid ceiling effects and following indications in the full model, we chose to focus 
on the most difficult faces (i.e., those presented for 200ms at low intensity); second, due to 
the consistent finding in the full model, we chose to focus on angry expressions; third, we 
included participants’ social traits as covariates. The resulting analysis was a 2 (Drug: 
OT/PL) x 2 (Training: CERT/placebo) univariate ANOVA with anxiety, mind reading and 
social skills as covariates, on participants responses to low intensity angry facial expressions 
presented at 200ms2. 
Replicating earlier findings, there was a main effect of training, F(1, 97) = 4.090, p = 
.046, 
 = .040, such that participants who completed the CERT identified more angry 
expressions correctly (M = 10.436, SE = 3.795), compared to those who completed the 
control training (M = -.669, SE = 3.944). There was no main effect of drug, F(1, 97) = .084, p 
= .772, 
 = .001 and no interaction, F(1, 97) = 1.303, p = .256, 
 = .013. All covariates 
were non-significant (anxiety: F(1, 97) = .652, p = .421, 
 = .007; mind reading: , F(1, 97) = 
.017, p = .896, 
 < .001; social skills: , F(1, 97) = .317, p = .575, 
 = .003). 
 
Discussion 
We present a pilot study comparing the effect of IN-OT administration against a 
psychological intervention designed to improve emotion recognition, CERT, in healthy male 
volunteers to investigate whether a psychological intervention or IN-OT provided the most 
social benefit, and whether a combined intervention strategy could provide additive benefit. 
There was no effect of IN-OT on emotion recognition (compared to PL), however, 
participants who completed the CERT identified more difficult angry facial expressions 
correctly (compared to those who completed a control training paradigm).  
 The finding that IN-OT did not improve emotion recognition contradicts several 
recent meta-analyses, which found that single administration studies of IN-OT had a reliable 
 
2 All covariates were included in one model. Variance Inflation Factor scores were assessed for each covariate. 
All VIFs were <1.2, we therefore conclude there was no multicollinerity between covariates. 
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effect on emotion recognition [2–4]. As noted previously however, our study recruited 
healthy volunteers with no known difficulties in emotion recognition, and results confirmed 
that participants were approaching ceiling effects for emotion recognition accuracy, despite 
incorporating both easy and difficult items into the outcome measure. Several studies have 
suggested that when incorporating moderating factors the positive social effects of IN-OT are 
often only seen in individuals who experience social difficulties [33,54,69–71]. We 
conducted an exploratory analysis to investigate this possibility, however, our measures of 
social difficulty did not impact our findings. We note, however, that there was very little 
variation in these scores, particularly in the AQ-S subscales. Our pilot study should therefore 
be replicated in various clinical samples in order to clarify whether IN-OT or emotion 
recognition training provides the greatest emotion recognition improvement. 
 In contrast, the finding that CERT improved recognition of angry expressions 
consistently, and in certain conditions other negative expressions, replicates previous research 
[49,50] in which participants who completed three sessions of the CERT demonstrated 
improved anger recognition and general negative emotion recognition with reduced anti-
social behaviour six months later. Emotion recognition training may therefore provide a 
specific and beneficial psychological intervention to support not only emotion recognition but 
also social interactions more widely.  
 There were numerous findings regarding the duration of stimuli presentation. This 
factor was specifically included based on a previous IN-OT meta-analysis [2] which found 
that while IN-OT had a small effect on improving overall emotion recognition, it had a 
moderate effect on improving emotion recognition for happy and angry facial expressions 
presented for <300ms, and fearful facial expressions presented for >300ms, suggesting that 
emotion-specific effects of OT may vary as a function of stimulus presentation. Contrary to 
our predictions, we found no significant interactions between drug condition and duration, 
but several with training. It is interesting, therefore, that in general, our results demonstrate 
that CERT also tended to improve emotion recognition around this 300ms cut-off, which 
Shahrestani and colleagues referred to as “early phase recognition” reflecting implicit 
processing [72]. Specifically, our finding that CERT improved recognition of ≤300ms angry 
facial expressions mirrors their IN-OT finding, which may explain why this effect was found 
for participants in the PL condition, and not for those in the OT condition. However, strong 
caution is advised when interpretating results from this interaction given the absence of any 
effect when comparing drug conditions directly. Thus, it would be interesting for future 
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research to investigate whether CERT is indeed targeting, or seeing improvements as a result 
of increased “early phase recognition”.   
 In contrast to our hypothesis based on the social salience hypothesis of OT [51,52], 
our data do not support the notion of an additive effect of IN-OT to psychological 
interventions. This finding may be explained by potential ceiling effects for emotion 
recognition, preventing a main and interaction effect of IN-OT, or may reflect a genuine 
finding replicating all four previous studies that have examined the additive potential of IN-
OT [53–57]. Regardless, several studies have now found no additive effect of IN-OT, yet 
there is continued interest in its therapeutic potential. It is important to reflect, therefore, on 
the caveats of IN-OT administration. 
Firstly, the pharmacokinetics of OT administration are not fully understood. New 
research is still examining which administration technique and concentrations are optimal for 
elevated OT concentrations and associated positive effects on social cognition [40,73–75]. 
The most common dosage of IN-OT administration, 24IU, is associated with increased OT 
concentrations for approximately two hours, at which time concentrations are returning to 
baseline [37–40]. Importantly, this research implies that therapeutic interventions of IN-OT 
would require multiple doses per day to maintain OT concentrations associated with the 
desired effects. Assuming one would want the effects to last during daylight hours, and that 
elevated OT concentrations last for two hours, this could require as many as seven doses a 
day. It is therefore not surprising that many of the clinical trials cited in the introduction 
failed to find a beneficial social effect of IN-OT as the majority of trials included only one or 
two doses of IN-OT per day [7,8,13,14,16,20,22–30,33,34,36,42]. Multiple doses a day, 
however, would not only be inconvenient for patients but also carry potential cost 
implications. To address this issue, a promising longer lasting compound has recently been 
developed [76–78], in which beneficial behavioural effects were seen 16-24hrs after 
administration, suggesting the compound has the potential to be delivered just once a day. 
These studies, however, were conducted in rodent models and the pharmacokinetics were not 
fully defined. The creation of OT superagonists provides exciting potential but extensive 
research is now required to understand whether the behavioural effects associated with 
previous OT administration studies are also apparent for these new compounds in humans, 
using different administration techniques. In the meantime, the existing literature utilising the 
traditional 24IU of IN-OT remains the most relevant literature, and therefore longevity and 
cost remain relevant concerns.  
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Secondly, relatively little is known about the long-term effects of IN-OT 
administration. A handful of trials have documented the behavioural effects of administering 
IN-OT for longer than 7 weeks [8,12,20,27,31,42,43], but only three assessed whether 
behaviour change was found during follow-up assessments after their interventions (ranging 
from 4-weeks to 1-year post intervention), [8,42,43]. Indeed, two of these studies were 
published just last year, highlighting the existing need to further understand the longevity of 
long-term IN-OT intervention. While more research is needed to understand the long-term 
behavioural effects, to our knowledge, no research has investigated the long-term 
pharmacokinetics. Whether, for example, individuals may become desensitised (and therefore 
require dose adjustments) over time is unknown.  
Thirdly, basic research into the social effects of IN-OT is carried out under strict 
supervision. This is primarily to ensure consistency in self-administration protocols in order 
to avoid differences in the dosage achieved. Guastella and colleagues (2013) published a long 
and detailed set of guidelines for researchers that would need to be imparted to patients if 
administration were to occur unsupervised (which is likely, assuming the need for multiple 
doses per day), if optimal doses are to be achieved.  
Finally, the majority of IN-OT research to date has been carried out on male 
populations. This is often due to logistical constraints around administering IN-OT to women, 
because there is some evidence that OT concentrations fluctuate over the menstrual cycle and 
with different contraceptives [60]. In addition, because OT is used to induce parturition, it 
can be necessary for female participants to complete a pregnancy test prior to taking part in a 
research study, which has additional cost and ethical implications. Indeed, the current study 
excluded females on this basis, and acknowledge this as an important limitation. 
Unfortunately, because the majority of research to date has been carried out on males it is 
unclear whether, or for what phenomena, sex differences are observed in behavioural effects 
of OT. There is therefore a need to include more mixed-sex samples in basic research to 
inform future clinical trials, particularly for disorders that specifically effect females (e.g., 
postnatal depression).  
There are several further limitations in the current study that should be acknowledged. 
First, and related to the previous discussion, although recruiting a male-only sample enabled 
us to replicate previous research using CERT, it remains an unanswered question whether 
CERT can improve emotion recognition in females. Second, the current study did not 
investigate the longevity of these effects. Evidence suggests that the CERT is associated with 
beneficial behavioural effects six months after completion [49,50]. As previously discussed, 
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the longevity of IN-OT’s behavioural effects is not fully understood; however, research 
suggests that the beneficial social effects are not sustained beyond the time that OT 
concentrations are elevated. Consequently, combining IN-OT with the CERT may be 
mutually beneficial in that OT administration prior to the CERT may improve the effects 
associated with the training and the CERT may increase the longevity of effects associated 
with IN-OT. Future research is needed to understand whether combined interventions are 
associated with better longevity compared to single interventions. Third, the current study 
recruited healthy volunteers and, as expected, participants performed well on the task and 
demonstrated a limited range in social difficulties, thus limiting our ability to investigate the 
potential moderating role of social traits on IN-OT effects as has been seen previously [e.g., 
51]. Fourth, the current study employed a visual based training program. A recent study 
found that children with autism significantly improved their ability to interpret emotions from 
auditory stimuli after an auditory training intervention [79]. Investigating training programs 
in different modalities may thus also prove fruitful for future research.  
 There are two specific strengths of the current study. First, the study recruited almost 
double the sample size (n = 104) to previous clinical studies [24,53,55] (and the same sample 
size to previous studies in healthy volunteers [56,57]) examining IN-OT and psychological 
interventions. Second, the study employed a full 2x2 design allowing us to directly compare 
whether participants who completed the CERT or received IN-OT displayed the greatest 
emotion recognition accuracy. Only two studies have utilised this approach [56,57], both 
published very recently (both also single administration trials in healthy volunteers), 
demonstrating the current need to understand whether psychological interventions by 
themselves can offer the same, or better, support to social functioning compared to IN-OT 
which has several draw backs. It is perhaps not a coincidence that both of these studies were 
also carried out in healthy volunteers. Clinical patients may be recruited via opportunity 
sampling if they are already participating in existing psychological interventions, however, 
further research in clinical samples using this full 2x2 design over a longer period of time is 
required to answer this important question.   
In conclusion, we found no effect of IN-OT and a positive effect of an emotion 
training program on healthy males’ emotion recognition. Future directions for this research 
include investigating whether emotion recognition specifically, or social training in general, 
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